Integra Therapeutics, a global leader in creating cutting-edge gene-writing tools to improve the efficacy, precision and safety of advanced therapies, today announced it will be presenting new pre-clinical data at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from May 13 to 17 in New Orleans.
“The presentation at ASGCT marks an important milestone in our work to develop safer and more capable cell engineering with our gene-writing platform with double digit editing efficiencies and multi gene integration for the next generation of cell therapies for oncological and autoimmune diseases” explains Dr Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics.
For the first time, the Integra Therapeutics’ technology has been used to created CAR-T cells, demonstrating the expression of more complex CARs (bispecific and with a kill switch) in a single DNA donor and simplifying the production process. The functionality of these CAR-T cells has also been shown compared to the methodology of market leaders and an improved ability to eliminate B-ALL tumoral cells and B cells from autoimmune diseases patients (i.e. lupus and rheumatoid arthritis) was demonstrated.
In addition, to the new FiCAT data for cell engineering, Integra Therapeutics will present results from CAR-T cells generated with novel CRISPR-Cas12l nucleases in combination with FiCAT, the result of the strategic agreement with Caszyme, which shows better efficiency than CRISPR-Cas9.
Presentation details
Title: Precise Gene Writing System for CAR-T cell therapy generation
Date & Time: May 14, 2025 / 5:30 pm-7:00 pm (local time)
Session Title: Gene Targeting and Gene Correction New Technologies
Location: Poster Session Hall I2
Published Abstract Number: 1140
Title: Development of viral-free FiCAT gene writing platform for liver-directed in vivo application
Date & Time: May 14, 2025 / 5:30 pm-7:00 pm (local time)
Session Title: Gene Targeting and Gene Correction New Technologies
Location: Poster Session Hall I2
Published Abstract Number: 1141
